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Abstract
Many drugs are chiral and their therapeutic activity depends on specific  
recognition of chiral biomolecules. The biological activity of enantiomers can also 
differ drastically in terms of toxicity and pharmacokinetics. Chiral natural biological 
molecules, such as nucleic acids, enzymes are targeted molecules for the development 
of anticancer drugs. The interest in chiral agents is logically a result of the different 
interaction with biomolecules leading in the end consequence to improve anticancer 
activity and maybe to less undesirable effects. This review outlines the effects of 
chirality on the efficiency of anticancer metal-based agents and potential organic 
drugs. A variety of up-to-date examples of structurally diverse chiral agents exhibit-
ing different mechanisms in their antitumor activity is presented.
Keywords: Chirality, anticancer, metal based, chiral complexes, drugs, organic metal 
agents
1. Introduction
Regardless of the origin, chirality is an integral part of biological process that 
derived their inherent asymmetry from the chirality of the fundamental building 
blocks of receptors – the L-amino acids. It would thus be expected that a recep-
tor protein derived from the enantiomeric D-amino acids would have the same 
fundamental properties, but exhibit opposing chirality of interaction. In addition, 
the macromoleculecular structures of biopolymers also give rise to chirality as a 
results of helicity. Such helical structures may have either a left or righ handed turn. 
In the case of DNA double helix and the protein α-helix, the biopolymers have a 
right-handed turn. As nature has a preference in terms of its chirality, enzymes and 
receptor system exhibit stereochemical preferences, particularly as many of natural 
substrates and ligands for these system, e.g. neurotrasmitters, endogenous opioids, 
and hormones [1].
It is now not surprising, that stereoisomers of drugs may differ in their 
pharmacodynamic activity at their biological target, or in their pharmacokinetic 
properties (absorption, distribution, and clearance by metabolism and excretion) 
[2, 3]. Enantiomers may differ both quantitatively and qualitatively in their bio-
logical activities. At one extreme, one enantiomer may be devoid of any biological 
activity, at the other extreme, both enantiomers may have qualitatively different 
biological activities. These stereoselective differences may arise not only from 
drug interactions at the pharmacological receptors, but also from pharmacokinetic 
events [4, 5].
Advances in chemical technology, especially in the methodology of stereoselec-
tive syntheses and stereospecific analyzes, together with regulatory measures, have 
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led to an increase in the number of new authorized chirally pure drugs over the 
last ten years, and this trend persists [6]. In contrast to the end of the last century, 
when about 55% of clinically used drugs were chiral and half of them were used 
as racemates, the current trend in the development of new chiral drugs is mainly 
towards substances containing pure one enantiomeric form [7, 8]. Currently, chiral 
formations of small molecules are an essential part of the discovery and develop-
ment of new anticancer medicines [2, 9].
2. Anticancer therapy
Cancer is a large group of diseases that can start in almost any organ or tissue of 
the body when abnormal cells grow uncontrollably and have the potential to invade 
or spread to other parts of the body. Cancer cells are formed when normal cells 
lose the normal regulatory mechanism that controls their growth and multiplica-
tion. If the cancer cells remain localized they are said to be benign. If the cancer 
cells invade other part of the body and set up secondary tumors a process known 
as metastasis - the cancer is defined as malignant and is life threatening [10]. A 
major problem in treating cancer is the fact that it is not a single disease. There are 
more than 200 different cancers resulting from different cellular effects, and so a 
treatment that is effective in controling one type of cancer may be ineffective on 
another [11].
Cancer is the second leading cause of death globally, behind only ischemic heart 
disease. Lung, prostate, colorectal, stomach and liver cancer are the most common 
types of cancer in men, while breast, colorectal, lung, cervical and thyroid cancer 
are the most common among women [12].
The primary treatment modalities include surgery, chemotherapy, radiation, 
and immunotherapy, etc. However, mainstay treatment is based on chemotherapy 
which is a viable alternative involving various natural and synthetic compounds 
that can kill or stop the unwanted proliferation of cancerous cells [13, 14].
The compounds used in the chemotherapy of cancer diseases are quite varied 
in structure and mechanism of action, including alkylating agents, antimetabolite 
analogs of folic acid, pyrimidine and purine; natural products, hormones and 
hormone antagonist; and a variety of agents directed at specific molecular targets. 
Most these of agents interacted with DNA or its precursors, inhibiting the synthe-
sis of new genetic material and causing damage to the DNA of both normal and 
malignant cells. Rapidly expanding knowledge about cancer biology has led to 
the discovery of entirely new and more cancer specific targets (e.g. growth factor 
receptors, intracelluar signaling pathways, epigenic processes, tumor vascularity, 
DNA repairs effect, and cell death pathway [15].
3. Chiral metal-based anticancer agents
Metal-based antitumor chemotherapeutics obtained prominence after the 
discovery of the cytotoxic effect of cisplatin - cis-diamminedichloroplatinum 
(II), cis-[Pt (NH3)2Cl2] – Figure 1. Currently, cisplatin is one of the most effective 
chemotherapeutic drug used for many solid malignancies [16]. The discovery of 
cisplatin stimulated efforts to investigate other platinum and non platinum metal-
containing compounds for their potential use in the treatment of cancer. In recent 
years, more attention has been devoted to complexes of other transition metals 
(ruthenium, gold, osmium, iridium, etc.) which offer a different mechanism of 
action and lower systemic toxicity compared to platinum-based drugs [17, 18].
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Chirality is one of the important paradigms that decide the precise structure of 
a particular anticancer drug and its interaction with the cancer molecular target. 
This is valid not only for organic drugs but also for metal-based drugs which are 
developed for anticancer application [19, 20]. An, example is oxaliplatin, which 
contains the chiral ligand (R, R)-cyclohexane-1,2-diamine. This platinum antineo-
plastic compound is more biologically active in comparison with its enantiomer 
contaning the ligand (S, S)-cyclohexane-1,2-diamine Figure 2 [20]. Interest in the 
development of chiral pure metal-based compounds for anticancer application is 
increasing.
Chiral metal-based anticancer drugs have been comprehensively reviewed in the 
literature [9, 21] therefore we will focus on selected examples to give the reader an 
overview of the most important developments. This review is limited to a variety 
of some recent examples of structurally diverse chiral agents exhibiting different 
mechanism in their anticancer effect.
Chirality in metal coordination complexes can be observed in two ways:
1. The metal centre has an asymmetric arrangement of ligands around it. This 
type of chirality can be observed predominantly in octahedral complexes and 
tetrahedral complexes,
2. The metal centre has a chiral ligand (i.e. the ligand itself has a non-superim-
posable mirror image).
Various methods have been used to denote the absolute configuration of opti-
cal isomers such as R or S, Λ or Δ, or C and A [22]. According to IUPAC rules the 
Figure 1. 
The chemical structures of clinically used platinum-based anticancer drugs.
Figure 2. 
The structures oxaliplatin with chiral ligands (a) 1R,2R-cyclohexane-1,2-diamine;  
(b) 1S,2S-cyclohexane-1,2-diamine.
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R/S convention is applied to enantiomers with tetrahedral geometry. In the case of 
compounds with geometries other than tetrahedral, the same principles are fol-
lowed as for the C/A convention (C for the clockwise and A for the anticlockwise 
priority sequence of ligands), and for bis and tris bidentate complexes the absolute 
configuration is designated Lambda Λ (left-handed) and Delta Δ (right-handed). 
Conformers with helical chirality are designated as δ (right-handed helix) and λ 
(left-handed helix).
3.1 Chiral Pt-based anticancer complexes
Since cisplatin was firstly approved by the US Food nd Drug Administration 
(FDA) in 1978, platinum complexes have become a class of important anticancer 
drugs [23]. Cisplatin has been widely employed to treat a variety of tumors includ-
ing ovarian, cervical, head and neck, non-small cell lung carcinoma, and testicular 
cancers, and is commonly used in combination regimens [24]. However, the clinical 
application of platinum drugs has several drawback including serious toxicity and, 
natural and acquired drug resistance [25, 26]. Therefore, much effort has been 
made to overcome the side effects and improve the antitumor activity of platinum-
based drugs [27–31].
To date, second and third generation platinum analogues, namely carboplatin 
and oxaliplatin, have been designated and approved for worldwide use. Carboplatin 
is effective in the treatment of ovarian carcinoma, lung, and head and neck cancers, 
while oxaliplatin is clinically approved for the treatment of colorectal cancer, which 
is resistant to cisplatin [32].
Other platinum compounds have regional approval, nedaplatin is used in 
Japan, lobaplatin is applied for treatment of chronic myeloid leukemia (China), 
heptaplatin is used for treatment of stomach cancer (in Korea). [32], though there 
is a little information about influence of its stereochemistry on biological effect 
Figure 1 [33].
It is widely accepted that the main biochemical mechanism of action of plati-
num (II) drugs involves the binding of the drug to DNA in the cell nucleus and 
subsequent interference with normal transcription, and/or DNA replication mecha-
nisms [34]. Cis platin becomes activated once it enters the cell. In the cytoplasm, 
chloride atoms on cisplatin are displaced by water molecules. This hydrolysed 
product is a potent electrophile that can react with any nucleophile, including the 
sulfhydryl groups on proteins and nitrogen donor atoms on nucleic acids. Cisplatin 
binds to the N7 reactive centre on purine residues and as such can cause deoxyri-
bonucleic acid (DNA) damage in cancer cells, blocking cell division and resulting 
in apoptotic cell death [35]. Some studies, using spectroscopics techniques and 
crystallography, have shown an energetically favourable interaction between the 
chiral ligands of platinum complexes stereoisomers and the DNA structure or small 
nucleotides [36–38].
Platinum drugs derived from chiral 1,2-diaminecyclohexane ligand (DACH) – 
were the first class of compounds used to investigate the relations between spatial 
configuration of the ligand and the ability of the complexes to form efficient 
adducts with DNA [39, 40].
Each DACH stereoisomer has a particularly stable bulk structure with a nearly 
planar shape for (RR) and (SS)-(DACH) dichloroplatinum (II) and an L-shaped 
molecule for the (RS) stereoisomer. As a consequence of these conformations, 
when the RS stereoisomer forms an adduct with DNA, significant steric hin-
drance is expected, resulting in a slower binding of the complexes to DNA as well 
as a different recognition and processing of the adducts formed. This theory has 
been confirmed by numerous cytotoxicity tests (predominantly towards human 
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tumor cell lines) on DACH and their structural analogues which have, in most 
cases, shown the same order of activity (RR > SS > RS) [41]. From the series of 
platinum drugs with DACH ligands only [PtCl2 (R, R-DACH) has been approved 
for clinical use [25].
Sometimes, when small modifications are made in the structure of chemically 
related compounds (for instance: a change in the substitution pattern of an aromatic 
ring or an alkyl chain) or in the conditions used to test the complexes (for instance: 
a change in the cell lines, a change from an in vitro to an in vivo test), a reversal 
of the stereoselectivity order can be detected [42, 43]. These findings suggest the 
possibility that interaction of platinum complexes with other biomolecules might 
be responsible for their stereoselectivity. These compounds are in most instances 
amino acids, proteins present in biological fluids and taking part in the distribution 
and metabolism of platinum complexes [41]. A difference in cellular accumulation 
between diastereoisomers was found in the platinum complex with phenyl deriva-
tive of chiral diamine ligands Figure 3 [44]. These findings supported the hypothe-
sis that stereoselectivity in cellular transport can also cause a different accumulation 
of platinum complexes in kidney and a different toxic effect of isomers [45].
The direct targeting of the G-quadruplex structure of DNA which is widely 
present in human telomeric DNA, transcription start sites, and promoter regions of 
genes responsible for cell apoptosis/growth and senescence, might play a key role 
in the anticancer action of chiral metal(II) complexes [46, 47]. The G-quadruplex 
structure is important in the control of a variety of cellular processes, including 
telomere maintenance, gene replication, transcription and translation [48, 49]. The 
induction/stabilization of quadruplex DNA is considered to be a potential target for 
the development of anticancer drugs [50, 51].
Platinum(II) complexes with chiral 4-(2,3-dihydroxypropyl)-formamide 
oxoaporphine R/S-(±)-FOA (1), R-(+)-FOA (2) and S-(−)-FOA ligands – Figure 4, 
showed significant antitumor activity caused by directly targeting G-quadruplex 
DNA [52]. Among these platinum(II) complexes, the complex with S-(−)-FOA was 
found to exhibit higher selectivity and telomerase inhibition via targeting telomere 
G4s in BEL-7404 cells, as well as inducing S phase arrest and telomeres/DNA dam-
age, which resulted in cell senescence and apoptosis. Similar results were also found 
in ruthenium(II) complexes with these chiral FOA ligands. The in vitro anticancer 
activity of the Ru(II) complex with S-(−)-FOA was higher compare to complex 
with -(±)-FOA (1), R-(+)-FOA [53].
Apart from platinum compounds, a number of other anticancer metal com-
plexes are currently being investigated. The main advantage of complexes contain-
ing a metal other than platinum is the different mechanism of action compared 
Figure 3. 
Examples of Platinum(II) complexes with chiral diamines ligands where stereochemical discrimination of 
cytotoxic activity was SS > RR > meso.
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to platinum-based chemotherapy, as well as a wider range of treated tumors, the 
ability to overcome resistance, and lower systemic toxicity [54, 55].
3.2 Chiral ruthenium anticancer complexes
Ruthenium complexes are promising candicates as chemotherapeutic agents 
because some of them have exhibited favorable in vitro and in vivo pharmacological 
profiles in different models including platinum-resistant cells [56, 57]. For instance, 
the ligand exchange kinetics of Pt(II) and Ru(II) complexes in aqueous solution, 
which is crucial for anticancer activity, are very similar; thus Ru is considered to 
be an alternative to platinum-based drugs. Many ruthenium compounds are less 
toxic than Pt-based drugs and some of them are quite selective for cancer cells. 
These facts may arise from the ability of ruthenium to mimic iron in binding to 
biomolecules [56, 58]. A number of ruthenium(II/III)-based anticancer agents have 
been developed to date, yet none of them are in clinical use as anticancer drugs. 
Currently, two Ru(III) complexes are in clinical studies: NAMI-A and KP1339 type 
ruthenium(III) coordination complexes based on N, Cl donor ligands Figure 5 [59].
The influence of chirality on anticancer effect has been reported primarily in 
the group of polypyridyl and organometallic Ru complexes and [9]. Wang et al. 
[60] presented a series chiral polypyridyl complexes (Δ-Ru1, Λ-Ru1, Δ-Ru2, Λ-Ru2, 
Δ-Ru3, and Λ-Ru3) – Figure 6 as mitochondria targeting anticancer agents. The 
cytotoxic activity of these ruthenium(II) complexes was tested against six selected 
Figure 4. 
The structures of chiral Platinum(II) complexes with chiral FOA ligand as G4-DNA and telomerase inhibitor.
Figure 5. 
The structures of ruthenium complexes in clinical studies.
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human cancer cell lines, (HeLa, A549, HepG2, MCF-7, BEL-7402, and MG-63), 
and one cisplatin resistant cell line. Δ-Ru1 was the most active anticancer agent, 
exhibiting cytotoxicity similar to that of cisplatin against the six cancer cell lines. 
Notably, this complex inhibited the growth of the cisplatin-resistant cell line 
A549-CP/R, suggesting that the anticancer mechanism of Δ-Ru1 differs from that 
of cisplatin. Λ-Ru1 displayed slightly lower toxicity than Δ-Ru1, which also seems 
to be attributed to the slightly less cellular uptake of ruthenium. In HeLa cells, the 
same relationship was found for Δ-Ru2 and Λ-Ru2, but the opposite relationship 
was found for Δ-Ru3 and Λ-Ru3.
Further analysis showed that Δ-Ru1 exerts its toxicity through the intrinsic 
mitochondria-mediated apoptotic pathway, which is accompanied by the regulation 
of Bcl-2 family members and the activation of caspases [60].
Some studies have highlighted the potential of polypyridyl Ru complexes to 
target G4 and telomerase [61, 62]. Sun et al. [63] revealed that enatinomers of 
Ruthenium complexes [Ru(phen)2(p-DMNP)]2+ − Figure 7 possessed binding 
affinities and significant selectivity for human G-quadruplex DNA. The Λ–Ru 
complext can stabilize human telomeric G quadruplex DNA slightly more than 
Δ–Ru and has a strong preference for G-quadruplex over duplex DNA. The specific 
recognition of HepG2 cells makes Λ–Ru complex a promising class of luminescent 
labels for (bio) imaging agents.
Chiral organometallic ruthenium (II) complexes have been studied as protein 
kinase inhibitors [64, 65]. In the case of chiral complexes containing bidentate 
staurosporine ligand – Figure 8 the (R)-enantiomer was a significantly more potent 
inhibitor in comparison to the (S)-enantiomer [65].
Figure 6. 
The structures of chiral polypyridyl Ru(II) complexes.
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Half-sandwich organometallic arene complexes have also been studied for anti-
cancer application, though studies of pure stereoisomers of arene complexes are 
limited, probably due to difficulties in their resolution [21]. Sadler et al. described the 
cytotoxicity of pure diastereoisomers of Ru arene complexes - Figure 9 [9, 66]. The 
R,S or S,R isomers showed higher cytotoxicity against the human ovarian cancer cell 
line (A2780) than the R,R or S,S compounds. However, the mechanism of the differ-
ent activities between the enantiomers was not reported.
Cuvea-Alique and co-workers [67] evaluated the anticancer activities of arene 
Ru(II) enantiomers witzzh aminooxime ligands- Figure 10. The oxime-containing 
Ru(II) compounds have shown potent anticancer activities against a broad range of 
different cancer cell lines, with no significant differences between the two enantiomers.
Other chiral organometallic complexes that have been studied for their antican-
cer properties include osmium [68, 69], iridium [70, 71], rhodium [72] and gold 
[73] complexes.
3.3 Chiral gold anticancer complexes
Gold complexes have emerged as a versatile and effective class of metal-based 
anticancer agents [74, 75]. Auranofin, (2,3,4,6- tetra-O-acetyl-1-(thio-κS)-β-
L-glucopyranosato)- (triethylphosphine) gold(I), is an orally administrated 
anti-arthritis drug which has also been clinically studied for its antiproliferative 
properties Figure 11 [74].
Figure 7. 
Examples of chiral polypyridyl Ru(II) complexes targeting G4 and telomerase.
Figure 8. 
The chemical structures of chiral Ru complexes with enantiomers of R- and S-staurosporine ligand.
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Based on these results different Au(I) complexes bearing stereogenic phosphine 
[76, 77], chiral N-heterocyclic carbenes ligands (NHC) [78, 79] have been synthe-
sized and tested as potential anticancer drugs.
Enantiomeric Au(I) complexes with a phospohorus stereogenic centre -  
Figure 12 has shown great toxicity against both suspended and adherent cancer 
cells but with marked difference s in their toxicity to healthy cells. The (R,R)-
enantiomers were more toxic against healthy mammalian cells compare to those 
of the (S,S)-enantiomer [76, 77].
Figure 9. 
The structures of diastereoisomers of organometallic arene Ru (II) complexes.
Figure 10. 
The structures of chiral organometallic arene Ru (II) complexes with aminoxime ligand.
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The mechanism of action of Au(I) complexes is thought to trigger apoptosis 
via inhibition of selenium- and sulfur-containing enzymes such as thioredoxin 
reductase (TrxR), glutathione peroxidase, cysteine protease or glutathione-S-
transferase [80].
The novel chiral Au(III) complexes containing chiral P stereogenic phosphine 
ligand: R,R and S,S- QuinoxP* (2,3-bis(tert-butylmethylphoshino)quinoxaline) 
were prepared Figure 13 [81]. The antiproliferative activities of the two compound 
were evaluated against panel of cell lines and exhibited cytotoxicity slightly higher 
than that of cisplatin and auranofin. However, no diffrence was found in the cyto-
toxic effect between the two enantiomers.
Figure 11. 
The structure of gold complex, which is under clinical investigation for treatment cancer.
Figure 12. 
Examples of enantiomeric phosphine-Au(I) complexes.
Figure 13. 
Chemical structures of the enantiomeric phosphine-Au(III) complexes.
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4. Chiral organic anticancer agents
The search for novel natural and synthetic compounds with potential anti-
tumor activity is a major goal of many research groups. The tests involve known 
compounds with proven biological activity that have not been previously used in 
oncology as well as newly synthesized molecules that are structural analogues of 
biologically active substances already used in the treatment of cancer [82].
4.1 Alkylating agents
Alkylating agents were among the first group of chemicals determined to be 
useful in cancer chemotherapy, and the largest drug group among conventional 
cytotoxic chemotherapeutics. They are so named because of their ability to add 
alkyl groups to negatively charged groups on biological molecules such as DNA and 
proteins [83]. Classical alkylating agents include nitrogen mustards, nitroso ureas, 
aziridines, and alkyl sulfonates. Nonclassical alkylating agents include hydrazine, 
triazene, and altretamines. In addition, the alkylating-like agent group, which 
similarly to alkylating agents functions by crosslinking with DNA, includes plati-
num compounds. The high clinical efficacy of one of the main classes of alkylating 
agents, nitrogen mustards, makes them the current choice for the first-line treat-
ment of different tumor types. However, severe side effects limit the therapeutic 
value of such compounds, and new effective compounds are required [84].
The group of bifunctional chloropiperidine derivatives has been revealed to possess 
novel efficient DNA-alkylating properties, leading to direct strand cleavage at guanine 
nucleotides and indirect effects on the human topoisomerase II enzyme [85, 86].
4.1.1 Chiral chloropiperidines
Carraro et al. [87] investigated series of racemic and enantiomerically pure 
monofunctional chloropiperidines – Figure 14. Derivatives of chloropiperidines 
demonstrated the ability to alkylate DNA in vitro. On a panel of carcinoma cell lines, 
M-CePs exhibited low nanomolar cytotoxicity indexes, which showed their remark-
able activity against pancreatic cancer cells and in all cases performed strikingly 
better than the chlorambucil control. Interestingly, stereochemistry modulated the 
activity of the chloropiperidines.
An analysis of the cytotoxicity of enantiomers N-butyl derivatives of chloro-
piperidines D-1 and L-1 in three cancer cell lines revealed that D-1 was the most 
Figure 14. 
Chemical structure of racemic chloropiperidines and enatiomerically pure compounds.
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active compound, again with a clear tropism for pancreatic cancer cells, while its 
enantiomer, L-1 enantiomer was less cytotoxic, with an eudismic ratio of ∼40 in 
the case of BxPC-3 cells. The direct damage observed to isolated DNA was not 
sufficient to explain their nanomolar cytotoxicity, especially when considering the 
enantiomeric couple.
The D-1 enantiomer turned out to be the most cytotoxic compound of the entire 
series, although it was inactive in the DNA cleavage assay. In contrast, its mirror 
image, L-1, found to efficiently nick and fragment the plasmid in vitro, happened to 
be much less cytotoxic.
The enantiomers also differed in permeation through an artificial membrane, 
that simulates passive diffusion. Because D-1 was the most cytotoxic but least 
permeable enantiomer, the permeation analysis of the chiral compounds suggests 
the involvement of active mechanisms of uptake into cells.
4.2 Inhibitors of  topoisomerases
4.2.1 Chiral epoxy-substituted chromones
Human DNA topoisomerases (Top) have been recognized as a good target 
molecule for the development of anticancer drugs because they play an important 
role in solving DNA topological problems caused by DNA strand separation during 
replication and transcription [88].
Jo et al. [89] designed and synthesized novel chiral epoxy-substituted chromone 
analogues -Figure 15 that exhibit an anticancer effect by inhibiting the DNA 
synthesis of cancer cells. Their ability to alkylate DNA and inhibit topo enzymes 
and cancer cell growth was evaluated.
In the brief structure–activity relationship analysis, no clear correlation was 
seen between stereochemistry and topos inhibitory and cytotoxic activity. However, 
compounds 6, 10 and 11 were more potent than the others in both Top I and IIα 
inhibitory activity.
The 5(R),7(S)-bisepoxy-substituted compound 11 showed the most potent cell 
antiproliferative activity against all tested cancer cell lines with particularly strong 
inhibition of K562 myelogenous leukemia cancer cell proliferation.
4.2.2 Chiral hydroxyanthraquinone analogs
Natural and synthetic analogs of hydroxyanthraquinones (e.g., anthracyclines, 
mitoxantrone and emodin) are additional prototypes for the design of anticancer 
drug candidates with the ability to bind double-stranded DNA and inhibit topoi-
somerases 1 and 2 mediated relaxation of supercoiled DNA [90, 91].
Derivatives of (4,11-dihydroxynaphtho[2,3-f]indole-5,10-dione) were identified 
as a promising scaffold for the search of agents active against resistant tumor cells 
[92]. Shchekotikhin et al. [93] explored new TopI and TopII antagonists based on a 
4,11-dihydroxy naphtho[2,3-f]indole-5,10-dione scaffold bearing the cyclic chiral 
diamine in the side chain - Figure 16.
Potent cytotoxicity (at submicromolar to low micromolar concentrations) 
against a panel of wild type mammalian tumor cells and isogenic drug resistant sub-
linies was observed for all novel derivatives of naphtho[2,3-f]indole-5,10-diones. 
Only isomer 7 induced the formation of specific DNA cleavage products similar 
for classical Top1 inhibitors camptothecin and indenoisoquinoline MJ-III-65. 
Importantly, the derivative of (R)- aminopyrrolidine 7 increased the life span of 
mice bearing P388 leukemia while its enantiomer 6 was inactive.
13
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4.3 Chiral thiosemicarbazones
Another group of potent anticancer agents is made up from chiral thiosemi-
carbazones derived from homochiral amines Figure 17 [94]. Their antiprolif-
erative activity was evaluated against several panels of cancel cell lines (A549 
(human alveolar adenocarcinoma), MCF-7 (human breast adenocarcinoma), 
HeLa (human cervical adenocarcinoma), and HGC-27 (human stomach carci-
noma) cell lines. Some of the compounds, especialy thiosemicarbazones with 
substituted hydroxyl group, 4-chlorophenoxy, 4-fluorophenoxy showed inhibi-
tory activities on the growth of cancer cell lines. Compounds with substituted 
piperidine ring exhibited higher activity against HCG-27 than taxol, which was 
uses as the standard. In every active thiosemicarbazone derivatives the (S)-
enantiomer was more active than (R)-enantiomer. The most active compounds 
the (S)-isomers of the thiosemicarbazone derivative with substituted piperidine 
group, also showed the best fit for the generated pharmacophore hypothesis. In 
the pharmacophore model, the (S)-enantiomer was better matched than the (R)-
enantiomer. This showed that the configuration of isomers greatly influenced 
their activity.
Figure 15. 
The structures of prepared chiral chromane analogs.
Figure 16. 
The chemical structures of naphthoindolediones with some chiral substituents.
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4.4 Chiral δ-iodo-γ-lactones
Compounds with both a lactone function and an aromatic ring in their structure 
are promising as potential anticancer agents [95, 96]. Four stereoisomers of δ-iodo-γ-
lactones with a 4-isopropylphenyl substituent at the β-position - Figure 18 were tested 
against a broad panel of canine cancer cell lines representing hematopoietic and mam-
mary gland cancers. The investigated isomers exerted higher activity against canine 
lymphoma/leukemia cell lines than against mammary tumors, whereas the configura-
tion of stereogenic centres of the examined compounds affected their activity.
Stereoisomers with the 4S configuration shown to be were more active, with 
the cis-(4S,5S,6R) isomer as the most potent. The investigated δ-iodo-γ-lactones 
act as an anticancer agent by the induction of apoptosis of canine cancer cells via a 
mitochondrial-mediated, caspase-dependent pathway [97].
5. Conclusions
Chirality has become a major task for the synthesis and development of 
drugs. One enantiomer of a chiral drug may be a medicine for particular disease 
Figure 17. 
The chemical structures of chiral thiosemicarbazones.
Figure 18. 
The structure of stereoisomers δ-iodo-γ-lactones with p-isopropylphenyl substituent.
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whereas; another enantiomer of the molecule may be not only inactive but can 
even be toxic. The pharmacological activity of chiral drugs depends mainly on the 
drug’s interaction with chiral biological molecules such as proteins, nucleic acids 
and bio membranes. This is valid not only for organic drugs, but also for metal-
based drugs which are developed for anticancer application. This review outlines 
the effect of chirality on the efficiency of anticancer metal-based drugs and 
interesting potential organic chiral drug molecules. The influence of stereoselec-
tivity on anticancer activity can hardly be generalized, it is manifested specifi-
cally for each individual chiral compound and depend on the type of cellular 
targets. However, knowledge of the stereochemistry of anticancer compounds can 
influence some critical processes underlying their toxicity towards cancer cells 
and provide a rational basis for the design of new antitumor drugs.
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